FDAnews
www.fdanews.com/articles/73560-protein-design-labs-sublicenses-to-genentech

PROTEIN DESIGN LABS SUBLICENSES TO GENENTECH

June 22, 2005

Protein Design Labs (PDL) reported that it has sublicensed to Genentech development and commercialization rights for antibody-drug conjugates directed against the PR1 antigen, which is frequently differentially expressed in prostate cancer. PDL will receive an upfront licensing fee, and is entitled to receive milestone payments and royalties on future sales under certain conditions. PDL's broad collaboration agreement with Seattle Genetics provides PDL with rights to develop antibody-drug conjugates to certain targets, including PR1.

()a href="http://www.biospace.com/news_story.cfm?StoryID=20418320&full=1" target="_blank">BioSpace